Featured News: Long-acting injectable cabotegravir is highly effective for the prevention of HIV infection in cisgender men and transgender women who have sex with men. View in "RECENT PUBLICATIONS".

Mission
  • Prioritize drugs and delivery platforms by identifying knowledge gaps & barriers in order to overcome limitations of available products.
  • Develop predictive strategies to identify the most desirable pharmacologic properties.
  • Include tuberculosis and viral hepatitis, which overlap the HIV epidemic, for which the availability of LA/ER drugs and formulations could most profoundly affect treatment and prevention.
News
Learn More
Use Our Services

Physiologically-based pharmacokinetic (PBPK) modelling and simulation of drug concentrations for LA/ER drug formulations can guide selection of dose, regimen, and formulation. A state-of-the-art Modeling and Simulation Core is a service offered to investigators working on preclinical and clinical development of LA/ER therapies.

Learn More
Explore LEAP Resources

A major role of LEAP is to provide researchers centralized access to relevant scholarly materials, data, publications, and conference proceedings from ongoing laboratory and clinical research that catalog progress in the field.

 

Learn More
Funding Opportunities

Finding funds for research can be a challenge.  The following resources are provided to help guide your efforts in seeking potential funding streams for your work.  We will update this section as new opportunities are released.

Learn More
How Can We Help?

LEAP is a central communications hub and data repository for investigators developing LA/ER treatment for HIV, tuberculosis, and viral hepatitis. What information or assistance are you looking for?

Learn More